INOVIO PHARMACEUTICALS, INC. 8-K

What Happened

• Inovio Pharmaceuticals, Inc. announced on April 2, 2026 that it entered an underwriting agreement with Piper Sandler & Co. to sell 12,500,000 shares of common stock together with accompanying Series A and Series B warrants in a public offering priced at $1.40 per unit. The company also granted the underwriters a 30‑day option to purchase up to 1,875,000 additional shares and corresponding warrants.
• The offering is expected to close on or about April 6, 2026, and, assuming no exercise of the underwriters’ option, net proceeds to Inovio are expected to be approximately $16 million.

Key Details

• Offering size: 12,500,000 shares of common stock plus accompanying Series A and Series B warrants; underwriter option for up to 1,875,000 additional shares/warrants (30 days).
• Price/terms: Combined public offering price of $1.40 per share with accompanying Series A and B warrants; Series A warrant exercise price $1.40 (or $1.399 per pre‑funded warrant), Series B same; pre‑funded warrants available with $0.001 exercise price.
• Warrant lifespan: Series A warrants immediately exercisable and expire one year from issuance; Series B warrants immediately exercisable and expire five years from issuance.
• Ownership limits: Warrant exercises are subject to beneficial ownership caps (default 4.99%, holder may elect 9.99% pre-issuance or adjust up to 19.99% in some cases with notice); if exercise would exceed the cap, holder may instead receive pre‑funded warrants.

Why It Matters

• This filing documents a near‑term equity financing that should provide Inovio roughly $16M in net cash (before any exercise of the underwriter option), which affects the company’s short‑term liquidity and operating runway.
• The issuance of shares and immediate‑exercise warrants creates potential future dilution if warrants are exercised (Series A within 1 year, Series B within 5 years). Ownership caps and pre‑funded warrant mechanics limit large immediate ownership changes.
• Investors should note the underwriter (Piper Sandler) and timing (expected close ~April 6, 2026) and watch subsequent SEC filings for the final close, any exercise of the overallotment option, and impacts on share count and cash balance.